3-(4-Bromo-2-fluorophenyl)-3-oxopropanenitrile, 97%, 2g

(R)-2-(Methylamino)propanoic acid hydrochloride, 95.0%, 25g

4',5'-Didehydro-5'-deoxyuridine, 98%, 10mg

2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoic acid, 1g

1-(1H-Pyrrolo[2,3-c]pyridin-3-yl)ethanone, 95.0%, 5g

5-Bromo-4-hydroxynicotinic acid, 95.0%, 1g

Plan PLPH 10x/0.25 phase contrast objective

7-Chloro-1H-pyrrolo[3,2-b]pyridin-3-amine, 98+%, 1g

Methyl 3-chloroquinoxaline-6-carboxylate, 98%, 1g

(2,2-Difluorobenzo[d][1,3]dioxol-4-yl)boronic acid, 95.0%, 5g

Disodium dihydrogenpyrophosphate, 95.0%, 1kg

1-(5-Bromo-6-methylpyridin-2-yl)piperazinehydrochloride, 95.0%, 1g

4-METHYLOCTAHYDRO-1H-PYRROLO[3,2-B]PYRIDINE, 95.0%, 250mg